These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 30026278

  • 1. Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.
    Jarrett KE, Lee C, De Giorgi M, Hurley A, Gillard BK, Doerfler AM, Li A, Pownall HJ, Bao G, Lagor WR.
    Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):1997-2006. PubMed ID: 30026278
    [Abstract] [Full Text] [Related]

  • 2. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia.
    Zhao H, Li Y, He L, Pu W, Yu W, Li Y, Wu YT, Xu C, Wei Y, Ding Q, Song BL, Huang H, Zhou B.
    Circulation; 2020 Jan 07; 141(1):67-79. PubMed ID: 31779484
    [Abstract] [Full Text] [Related]

  • 3. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.
    Roche-Molina M, Sanz-Rosa D, Cruz FM, García-Prieto J, López S, Abia R, Muriana FJ, Fuster V, Ibáñez B, Bernal JA.
    Arterioscler Thromb Vasc Biol; 2015 Jan 07; 35(1):50-9. PubMed ID: 25341796
    [Abstract] [Full Text] [Related]

  • 4. AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.
    Somanathan S, Jacobs F, Wang Q, Hanlon AL, Wilson JM, Rader DJ.
    Circ Res; 2014 Aug 29; 115(6):591-9. PubMed ID: 25023731
    [Abstract] [Full Text] [Related]

  • 5. In Vivo Gene Editing in Lipid and Atherosclerosis Research.
    De Giorgi M, Jarrett KE, de Aguiar Vallim TQ, Lagor WR.
    Methods Mol Biol; 2022 Aug 29; 2419():673-713. PubMed ID: 35237996
    [Abstract] [Full Text] [Related]

  • 6. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
    Lu H, Howatt DA, Balakrishnan A, Graham MJ, Mullick AE, Daugherty A.
    Arterioscler Thromb Vasc Biol; 2016 Sep 29; 36(9):1753-7. PubMed ID: 27470509
    [Abstract] [Full Text] [Related]

  • 7. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
    Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S.
    Circulation; 2013 Jun 18; 127(24):2403-13. PubMed ID: 23690465
    [Abstract] [Full Text] [Related]

  • 8. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
    Tavori H, Giunzioni I, Predazzi IM, Plubell D, Shivinsky A, Miles J, Devay RM, Liang H, Rashid S, Linton MF, Fazio S.
    Cardiovasc Res; 2016 May 15; 110(2):268-78. PubMed ID: 26980204
    [Abstract] [Full Text] [Related]

  • 9. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.
    Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN, Cowan CA, Rader DJ, Musunuru K.
    Circ Res; 2014 Aug 15; 115(5):488-92. PubMed ID: 24916110
    [Abstract] [Full Text] [Related]

  • 10. A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification.
    Goettsch C, Hutcheson JD, Hagita S, Rogers MA, Creager MD, Pham T, Choi J, Mlynarchik AK, Pieper B, Kjolby M, Aikawa M, Aikawa E.
    Atherosclerosis; 2016 Aug 15; 251():109-118. PubMed ID: 27318830
    [Abstract] [Full Text] [Related]

  • 11. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD, Lee SE, Yang J, Lee HC, Shin D, Lee H, Lee J, Jin S, Kim S, Lee SJ, You J, Park HW, Nam KY, Lee SH, Park SW, Kim JS, Kim SY, Kwon YW, Kwak SH, Yang HM, Kim HS.
    Eur Heart J; 2020 Jan 07; 41(2):239-252. PubMed ID: 31419281
    [Abstract] [Full Text] [Related]

  • 12. Spontaneous severe hypercholesterolemia and atherosclerosis lesions in rabbits with deficiency of low-density lipoprotein receptor (LDLR) on exon 7.
    Lu R, Yuan T, Wang Y, Zhang T, Yuan Y, Wu D, Zhou M, He Z, Lu Y, Chen Y, Fan J, Liang J, Cheng Y.
    EBioMedicine; 2018 Oct 07; 36():29-38. PubMed ID: 30243490
    [Abstract] [Full Text] [Related]

  • 13. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L, Yang X, Li Q, Zeng P, Liu Y, Liu L, Chen Y, Yu M, Ma C, Li X, Li Y, Zhang R, Zhu Y, Miao QR, Han J, Duan Y.
    Arterioscler Thromb Vasc Biol; 2017 Jul 07; 37(7):1290-1300. PubMed ID: 28546220
    [Abstract] [Full Text] [Related]

  • 14. Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.
    Kumar S, Kang DW, Rezvan A, Jo H.
    Lab Invest; 2017 Aug 07; 97(8):935-945. PubMed ID: 28504688
    [Abstract] [Full Text] [Related]

  • 15. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing.
    Edraki A, Mir A, Ibraheim R, Gainetdinov I, Yoon Y, Song CQ, Cao Y, Gallant J, Xue W, Rivera-Pérez JA, Sontheimer EJ.
    Mol Cell; 2019 Feb 21; 73(4):714-726.e4. PubMed ID: 30581144
    [Abstract] [Full Text] [Related]

  • 16. Local effects of human PCSK9 on the atherosclerotic lesion.
    Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF, Fazio S.
    J Pathol; 2016 Jan 21; 238(1):52-62. PubMed ID: 26333678
    [Abstract] [Full Text] [Related]

  • 17. Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9.
    Wang L, Breton C, Warzecha CC, Bell P, Yan H, He Z, White J, Zhu Y, Li M, Buza EL, Jantz D, Wilson JM.
    Mol Ther; 2021 Jun 02; 29(6):2019-2029. PubMed ID: 33609733
    [Abstract] [Full Text] [Related]

  • 18. Generation of hyperlipidemic rabbit models using multiple sgRNAs targeted CRISPR/Cas9 gene editing system.
    Yuan T, Zhong Y, Wang Y, Zhang T, Lu R, Zhou M, Lu Y, Yan K, Chen Y, Hu Z, Liang J, Fan J, Cheng Y.
    Lipids Health Dis; 2019 Mar 18; 18(1):69. PubMed ID: 30885208
    [Abstract] [Full Text] [Related]

  • 19. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
    Wang X, Raghavan A, Chen T, Qiao L, Zhang Y, Ding Q, Musunuru K.
    Arterioscler Thromb Vasc Biol; 2016 May 18; 36(5):783-6. PubMed ID: 26941020
    [Abstract] [Full Text] [Related]

  • 20. Induction of atherosclerosis in mice and hamsters without germline genetic engineering.
    Bjørklund MM, Hollensen AK, Hagensen MK, Dagnaes-Hansen F, Christoffersen C, Mikkelsen JG, Bentzon JF.
    Circ Res; 2014 May 23; 114(11):1684-9. PubMed ID: 24677271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.